leisure time -WSS

leisure time

author：knowledge 2025-10-01 22:16:44 - browse：35

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Maisha Meds is a PBM, but don't call it that

knowledge

WSS

First Opinion Podcast: Long Covid needs a new approach

Solve the antibiotic resistance crisis with preventive drugs

To bolster infectious disease surveillance, genomics powerhouses team up

There's an unseen cost to disruptive road

STAT Readout Newsletter: Today's biggest biotech updates

Maisha Meds is a PBM, but don't call it that

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Jerome Adams on the need for new antivirals for Covid

FDA gives detailed accounting of AI

Psychedelics group wrestles with new pharma identity

Studies point to risks of excluding people with obesity from drug trials

New air purifier tech could be key to improving indoor air quality

CEOs share strategies for surviving biotech slump

Supreme Court strikes down use of affirmative action

Dana Farber says 6 studies to be retracted and 31 corrected

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

focus

To bolster infectious disease surveillance, genomics powerhouses team up

CEOs share strategies for surviving biotech slump

Pumping milk in bathrooms at health conferences is common

Inaction leaves children at risk from dangerous chemotherapy drug

Maisha Meds is a PBM, but don't call it that

CEOs share strategies for surviving biotech slump

hotspot

Wikipedia

knowledge

hotspot